Introduction
Hepatitis infection is one of the major global health problems involving more the 2 billions people throughout the world. To date more than 370 million people are chronically infected with HBV worldwide, leading to chronic liver disease and development of Hepatocellular carcinoma (HCC) in many cases. Chronically carriers of this disease are living throughout the world mostly in the South East of Asia (1) (2) (3) (4) . It is estimated that more than 3% of Iranian population to be the chronic carriers of the viruses (5, 6) . Approximately 40 millions out of 370 million chronic carriers are died due to hepatic cirrhosis while up to 60 millions are passing out due to hepatocellular carcinoma (3) (4) (5) . Recent studies have shown that some HBsAg negative individuals may develop some sort of chronic hepatitis B which is detectable employing some new laboratory diagnosis techniques such as molecular tests (7) (8) (9) . To date, 8 genotypes (called A-H) that differ by definition in at least 8% of their complete genome have been found. The genotypes can be further divided into 24 subgenotypes that differ by at least 4% from each other (10) . In general the infection with HBV can lead to a wide spectrum of clinical manifestations, e.g. self-limited acute or fulminant hepatitis, asymptomatic infection, or chronic hepatitis with progression to liver cirrhosis that can lead to hepatocellular carcinoma (10) . Although HBV is a DNA virus, it is highly variable under immunity or drug induced selection pressure, resulting in vaccine-related escape mutants and drug resistance. In human during decades HBV has had many mutations by which this agent has been able to escape from the immune system reactions so that HBV by far has changed its life style. One of the well know mutation for HBV has been occurred in Pre core region by which C gene is unable to produce HBsAg but producing HBcAg instead. This special mutation bas been reported mostly in Asia and East European countries. Chronic hepatitis B with negative HBsAg is usually seen with mutation in S gene (11) . Considering such mutations into account, it seems necessary to employ the new molecular techniques to analyze the diagnosis of HBV DNA in chronic carriers and healthy individuals whose sera HBsAg was negative with ELISA either qualitatively or quantitatively. We aimed to evaluate the viral DNA in biological fluids of chronic hepatitis patients compared to a control group.
Materials and Methods
Seventy patients with chronic hepatitis B as case and 70 individuals from healthy people living in Ilam as the control group were randomly selected to participate in this study. PCR and Real Time PCR were applied to test the samples for HBV. ELISA is the standard test for diagnosis of many diseases including HBV which is routinely used in medical Laboratories using HBsAg (12) (13) (14) . The limitation of this test is that usually 50-60 days post infection, the HBsAg can be detected, though when the viremia is low, detection my not been happened , this is why the quantitative PCR is recommended (15) and is considerably being used increasingly as it is used for evaluation of treatment and for progress analysis of the disease. The quantity of viral DNA in sera is one of the most important parameter used for predicting the liver cancer and also for analyzing the antiviral treatment efficacy. One of the best reliable methods in diagnosing the HBV is Real Time PCR which needs a standard in order to determine the quantity of HBV DNA comparing to standard curve (16) (17) (18) . The PCR and Real Time PCR were used in this study as briefly describes here: Serum viral DNA was extracted using Gelbased filter tube including silica gel. 200λ of sample was added to 200λ lysing buffer, adding 50λ proteinase K, incubating at 65•C for 10 min. 200λ isopropanol was added and washing was applied few times using alcoholic buffers, yielding DNA at the end. The DNA was transferred to the sterile tubes and kept for the next steps. Serum viral DNA was extracted as follows: A lysing buffer containing tris-Hcl (500mM), ethidium bromide (20mM) and sodium chloride (10mM) was prepared. 150μl of the above lysing buffer was added to 30λ of each ear cerumen, mixed well and incubated at 65•c for 1 hour. For qualitative PCR a master mix solution including tag-polymerase, loading buffer, dNTp and two following primers was used: F: 5́ -CAC TCA CCA ACC TCT TGT CC -3́ R: 5́ -TGA AGT TTC CGT CCG AAG GT -3́ The thermal reaction is summarized in Table 1 . 
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PCR was performed using Ependorf Vapa Protect (Germany). Real time PCR was performed using Aj Roboscreen kit (Germany) and BioRad CF×9 
Discussion
HBV DNA has been detected in many human fluids including serum, saliva, tears, urine, amniotic fluid, seminal fluid, sweat, bile, milk, and recently cerumen and ear atorrhea (19, 20 ) . Car-riers of HBV in Iran have already been estimated to be about 3% (6, 21) while the results of the current study revealed that about 7% are the real chronic carriers of HBV amongst healthy people living in the community. It seems that different procedures applied in the studies previously have been done and also in current study can justify the different aspects of these studies either in the field of their focus or in the spectrum of their results. PCR and Real Time PCR are both superior to the ELISA particularly when different biological fluids are tested. The mean DNA copy/ml for cerumen & serum was 1.56×10 6 and 5.459×10 5 respectively. Kolciogu MT et al., who had studied 40 patients with chronic hepatitis B, reported that 12.5% of patients had HBV DNA in their creumen while 100% showed HBV DNA in their sera using Real Time PCR. The mean copy of HBV in cerumen & serum was reported to be 1.2×10 4 and 2.4×10 7 respectively (22). Goh Eui et al. had studies 30 patients who showed HBV DNA in their serum, and reported that 66.7% of those patients had HBV DNA in their cerumen as well (20) . As can be seen from the above studies comparing to the current study, there is a significant difference between the results of our study and the above ones. Results of the current study not only confirmed all HBsAg positive patients with ELISA showed HBV DNA in their sera and 87% of them showed HBV DNA in their cerumen but also about 7 % of healthy individuals in control group had HBV DNA taking into account as chronic carriers of HBV. As we have studied the healthy people, the chronic carriers have been detected, while the others studies done so far had not shown this. In conclusion this is the first study detecting HBV DNA from the cerumen of 5 individuals as chronic carrier of HBV amongst control group studied in Iran. After Turkey and Korea apparently this is the next study about molecular detection of ceruman HBV DNA, which is one important issue as detection of HBV DNA in cerumen is a more easy procedure to be performed and also the real time PCR is a very precise method. Another important finding of the current study is stressing on this point that HBsAg screening is not as reliable as molecular techniques such as Real time PCR in detecting HBV DNA in healthy people as chronic carriers. Real time PCR detected carriers in control group where HBsAg was not able to perform this. On the other hand it is merely important that having negative results of HBsAg in sera by ELISA does not necessarily means that there is no infection but the strength of such assay is limited. The source of infection and also the biological fluid to be tested are as important as the type of assay.
Ethical considerations
Ethical issues (Including plagiarism, Informed Consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc) have been completely observed by the authors.
